imipenem/cilastatin/relebactam

The combination injection of imipenem, cilastatin, and relebactam is prescribed for the treatment of complicated bacterial infections occurring in various parts of the body, such as the kidneys and stomach. Additionally, this medication is effective in treating hospital-acquired and ventilator-associated bacterial pneumonia.

If your symptoms do not improve or worsen, please contact your doctor. You should start experiencing relief within the initial days of receiving imipenem and cilastatin injection.

Administer 500 mg of IV every 6 hours. Transition to an appropriate oral regimen once symptoms improve, pending culture and susceptibility results. The total duration of therapy can range from 5 to 14 days, depending on the clinical response and the chosen antimicrobial to complete the regimen (Ref).

Carbapenems (imipenem, meropenem, doripenem) exhibit a wide range of activity against various types of bacteria, including Gram-positive, Gram-negative, and anaerobic bacteria. However, they do not have any effect on Enterococcus faecium, methicillin-resistant Staphylococcus aureus, and Stenotrophomonas maltophilia.

Sepsis patients are treated with a variety of broad-spectrum antibiotics, including imipenem, vancomycin, linezolid, daptomycin, piperacillin-tazobactam, meropenem, doripenem, ertapenem, and ceftriaxone.

Imipenem, cilastatin, and relebactam injection is administered to adults to address specific severe urinary tract infections, such as kidney infections, and severe abdominal infections when alternative treatment options are limited or unavailable.

According to I. Phillips’ abstract, Imipenem has shown effectiveness as an antistaphylococcal agent against both MRSA and MSSA infections.

For adults and children 12 years and older, the recommended dosage is 250mg to 1g administered intravenously every 6 to 8 hours, or 500 to 750mg administered intramuscularly every 12 hours, depending on the severity of the infection. For children under 12 years old, the appropriate use and dosage should be determined by a doctor.

Precautions should be taken while using this medicine. It is possible for patients to experience tremors or seizures. If you have a history of seizures and are currently taking anticonvulsants, it is important to continue taking them unless instructed otherwise by your doctor. Additionally, some patients may experience diarrhea as a side effect of the imipenem and cilastatin combination.

Recarbrio, a fixed-dose combination medication, contains imipenem/cilastatin/relebactam and is used as an antibiotic.

The U.S. FDA has approved a combination antibiotic called imipenem-cilastatin/relebactam (brand name Recarbrio) on July 17, 2019. This antibiotic is intended for the treatment of complicated urinary tract infection (cUTI) or complicated intra-abdominal infection (cIAI) in adults.

Recarbrio, a fixed-dose combination medication known as Imipenem/cilastatin/relebactam, is an antibiotic used to treat complicated urinary tract and complicated intra-abdominal infections. It received approval for use in the United States in 2019.

The powder form of imipenem and cilastatin injection is intended to be mixed with a liquid and administered either intravenously or intramuscularly. When given intravenously, it is typically infused slowly over a span of 20 minutes to 1 hour, with a frequency of every 6 or 8 hours.

Imipenem has shown effectiveness as an antistaphylococcal agent for treating both MRSA and MSSA infections.

Relebactam belongs to a group of drugs known as beta-lactamase inhibitors. Its mechanism of action involves inhibiting the destruction of imipenem by bacteria. It is important to note that antibiotics like imipenem, cilastatin, and relebactam injection are ineffective against colds, flu, and other viral infections.

Imipenem/cilastatin, marketed as Primaxin and other brand names, is an effective antibiotic for treating various bacterial infections. This medication is a combination of imipenem and cilastatin.

Imipenem, also known as Primaxin and developed by Merck scientists Burton Christensen, William Leanza, and Kenneth Wildonger in the mid-1970s, is a synthetic ?²-lactam antibiotic classified as a carbapenem.

For adults and children 12 years and older, the recommended dosage is 250mg to 1g administered intravenously every 6 to 8 hours, or 500 to 750mg administered intramuscularly every 12 hours, depending on the severity of the infection. For children under 12 years old, the appropriate use and dosage should be determined by a doctor.

Cilastatin/imipenem/relebactam is a medication manufactured by Merck Sharp and Dohme.

For adolescents 15 years and older (and weighing at least 30 kg) and adults, the recommended dose is 1000 mg (2 vials) taken twice daily with a minimum of 10 hours between infusions. The maximum daily dose should not exceed 2000 mg.

For individuals with renal insufficiency and a creatinine clearance (CrCl) of 20-40 ml/minute, the recommended dose is 750 mg taken every 12 hours. For those with a CrCl less than 20 ml/minute, the recommended dose is 500 mg taken every 12 hours.

Imipenem & Cilastatin Cilaxtra 500 mg Injection is manufactured by Alkem Laboratories Ltd.

When imipenem and cilastatin are used together in a 1:1 ratio, cilastatin prevents the breakdown of imipenem and allows for about 70% of the dose to be excreted in the urine as active imipenem.

Imipenem is a carbapenem antibiotic that has a wider range of antimicrobial activity and higher effectiveness compared to other beta-lactam antibiotics. It is commonly administered alongside cilastatin, which helps to prevent the breakdown of imipenem by inhibiting a specific enzyme found in the kidney tubules.

Possible side effects of this medication include swelling, redness, pain, or soreness at the injection site. Additionally, there is a rare chance of experiencing upset stomach, nausea, vomiting, or diarrhea. If any of these symptoms persist or worsen, it is important to inform your doctor or pharmacist immediately.

Imipenem/cilastatin and meropenem, which are carbapenem antibiotics, are administered intravenously (IV) through a 30 to 45-minute infusion.

It is recommended that the maximum total daily dosage does not exceed 4 grams per day. The medication should be administered through intravenous infusion, with a dosage of 500 milligrams over a period of 20 to 30 minutes. For a dosage of 1,000 milligrams, the infusion should be given over a period of 40 to 60 minutes. If patients experience nausea during the infusion, the rate of infusion may be slowed.

Imipenem, a semisynthetic thienamycin, exhibits a broad range of antibacterial activity against both gram-negative and gram-positive aerobic and anaerobic bacteria, including numerous strains that are resistant to multiple antibiotics. Additionally, it remains stable in the presence of many beta-lactamases.

Imipenem, which was first introduced in Canada in 1987, quickly gained recognition for its extensive antibacterial capabilities, surpassing all other antibiotics available at the time (3,4). While it is effective in treating various severe infections, it is not recommended for meningitis.

Caution should be exercised when coadministering these medications as it may increase the risk of seizures. It is recommended to avoid this combination unless the potential benefits outweigh the risks. Additionally, imipenem/cilastatin may reduce the effectiveness of microbiota oral through pharmacodynamic antagonism. It is advised to avoid this combination or consider using an alternate drug.

Meropenem is particularly effective against Gram-negative bacilli, while imipenem-cilastatin is more effective against Gram-positive cocci. However, meropenem’s stability allows for longer infusions and it has milder adverse effects on the central nervous system compared to imipenem-cilastatin.

Imipenem exhibits strong activity against Pseudomonas aeruginosa as well. Additionally, it effectively targets both anaerobic gram-positive and gram-negative bacteria, including all subspecies of Bacteroides fragilis (Hellinger and Brewer, 1999; Scholar and Pratt, 2000; Kucers et al, 1997).

Carbapenems (imipenem, meropenem, doripenem) exhibit a wide range of activity against various types of bacteria, including Gram-positive, Gram-negative, and anaerobic bacteria. However, they do not have any effect on Enterococcus faecium, methicillin-resistant Staphylococcus aureus, and Stenotrophomonas maltophilia.

Belonging to the carbapenem group of drugs, Imipenem disrupts the cell wall of bacteria. Cilastatin, on the other hand, hinders the functioning of dehydropeptidase I, which stops the breakdown of imipenem. The combination of imipenem and cilastatin was introduced in 1987 and has been included in the World Health Organization’s List of Essential Medicines.

Imipenem is utilized to treat bacterial infections in the lower respiratory tract, urinary and sexual tracts, bones, joints, skin, soft tissues, intraabdominal and gynecological infections, bacterial septicemia, and endocarditis. However, it is important to note that imipenem can be deactivated by enzymes in the kidneys.

Relebactam functions by inhibiting the hydrolysis of imipenem, enabling it to effectively kill bacteria. This beta-lactamase inhibitor is capable of blocking various types of beta-lactamases, such as Ambler class A and Ambler class C enzymes, thereby safeguarding imipenem from degradation within the body.

Imipenem has shown effectiveness as an antistaphylococcal agent for treating both MRSA and MSSA infections.

Imipenem is produced by synthesizing thienamycin, which is obtained from Streptomyces cattleya, and reacting it with methyl formimidate. Unlike penicillins and cephalosporins, which have an aminoacyl group attached to the beta-lactam ring, imipenem has a hydroxyethyl side chain.

The drug labels of PRIMAXIN® i.v., also known as Imp/Cil for injection, warn about the potential risk of acute renal failure, oliguria/anuria, polyuria, and urine discoloration. These adverse effects are more frequently observed in pediatric patients, with an incidence rate higher than 1%.

The price of a 10-powder supply of cilastatin/imipenem intravenous powder for injection (500 mg-500 mg) can range from approximately $96, depending on the pharmacy you choose.